• If you are wondering whether Cencora stock is offering good value right now, its recent valuation signals suggest it is worth a closer look.
• The share price last closed at US$286.95, with returns of 5.6% over the past week and 6.0% over the past month, while the return so far this year has declined 15.3% and the return over the last year has declined 2.5%. Over three years and five years, returns were 54.5% and 159.5% respectively.
• Recent coverage of Cencora has focused on its role in the healthcare sector and how investors are reassessing companies that sit at the heart of critical supply chains. This context helps frame recent share price moves as part of a wider re-rating of healthcare service providers.
• Cencora currently has a valuation score of 6/6. The rest of this article will look at how different valuation approaches arrive at that result, while also pointing to an even more complete way to think about valuation at the end.

Approach 1: Cencora Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Cencora stock could be worth by projecting future cash flows and discounting them back to today in dollar terms. The idea is simple: it asks what all those future cash flows are worth in present-day money.

For Cencora, the model used is a 2 Stage Free Cash Flow to Equity approach, starting from last twelve months free cash flow of about $1.66b. Analyst estimates underpin projections for the next few years, and from there Simply Wall St extrapolates cash flows further out. By 2030, projected free cash flow is $4.38b, with interim years ranging from about $3.18b in 2026 to $4.53b in 2035 on the current forecast path.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of $484.52 per share. Compared with the recent share price of $286.95, this implies an intrinsic discount of 40.8%, which indicates Cencora is trading at a substantial discount to this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 40.8%. Track this in your watchlist or portfolio, or discover 43 more high quality undervalued stocks.

Approach 2: Cencora Price vs Earnings

For a profitable company like Cencora, the P/E ratio is a useful way to gauge how much investors are paying for each dollar of earnings. It ties the share price directly to earnings, which are a key driver of long term value for many businesses.

What counts as a "normal" or "fair" P/E usually reflects expectations for future earnings growth and the risks around those earnings. Higher expected growth or lower perceived risk can justify higher P/E ratios, while slower growth or higher risk can point to lower P/E levels.

Cencora currently trades on a P/E of 21.91x. This sits below the Healthcare industry average of 23.67x and the peer group average of 29.56x. Simply Wall St also calculates a proprietary “Fair Ratio” of 24.74x for Cencora, which is an estimate of the P/E you might expect given factors such as its earnings growth profile, industry, profit margins, market capitalization and risk characteristics.

This Fair Ratio can be more informative than a simple comparison with peers or the industry, because it adjusts for differences in growth, risk and profitability rather than assuming all companies should trade on the same multiple. With Cencora’s current P/E below the Fair Ratio, the stock appears undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Cencora Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, a simple framework on Simply Wall St’s Community page that lets you attach your story about Cencora to the numbers. You can link your assumptions for revenue, earnings, margins and fair value to a clear forecast, then compare that Fair Value with today’s price to help decide whether to act. The Narrative itself automatically updates as fresh news or earnings arrive, and different investors can still reasonably land on very different fair values for Cencora based on their own expectations for its role in healthcare supply chains.

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.